Ashling Wahner

An indirect comparison study in relapsed/refractory chronic lymphocytic leukemia demonstrated survival benefits with zanubrutinib vs acalabrutinib.

Eric S. Winer, MD, discusses the mechanism of action of emavusertib and preliminary findings from the TakeAim Leukemia trial in acute myeloid leukemia.

The President’s Cancer Panel has issued an initial assessment of the National Cancer Plan with recommendations to accelerate cancer care developments.

The European Medicines Agency has validated a marketing authorization application seeking the approval of nirogacestat for patients with desmoid tumors.

The National Comprehensive Cancer Network recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.

Andre H. Goy, MD, discusses how the ZUMA-18 trial data support the benefit of earlier-line use of brexucabtagene autoleucel in mantle cell lymphoma.

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.

The Committee for Medicinal Products for Human Use has recommended the approval of cilta-cel for earlier-line relapsed/refractory multiple myeloma.

Swissmedic has accepted for review a marketing authorization application seeking the approval of Piflufolastat (18F) for prostate cancer.

Jan Joseph Melenhorst, PhD, emphasizes how research investigating chronic lymphocytic leukemia biology may result in more targeted CAR T-cell products.

A biologics license application for linvoseltamab in relapsed/refractory multiple myeloma has been accepted for priority review by the FDA.

IMM-1-104 received FDA fast track designation for use in patients with pancreatic ductal adenocarcinoma who have progressed on 1 line of treatment.

Vorasidenib has been granted regulatory submission acceptance by the FDA and EMA for IDH-mutant diffuse glioma.

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

A new drug application for Dasynoc, a protein kinase inhibitor product candidate for patients with chronic myeloid leukemia, has been accepted by the FDA.

Michael R. Bishop, MD, discusses the rationale for and key findings from the FELIX trial of obe-cel in B-cell acute lymphoblastic leukemia.

AlphaMedix has received breakthrough therapy designation from the FDA for use in select patients with gastroenteropancreatic neuroendocrine tumors.

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.

Hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery improved progression-free survival in stage III epithelial ovarian cancer.

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Rona Yaeger, MD, discusses a study of second-line sotorasib plus panitumumab in patients with KRAS G12C–mutated colorectal cancer.

Talha Badar, MBBS, MD, discusses the FDA approval of ivosidenib for patients with myelodysplastic syndrome and the future management of this disease.

The FDA has granted priority review to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive advanced solid tumors.